StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
14
Publishing Date
2022 - 08 - 06
1
2022 - 06 - 17
1
2022 - 06 - 02
1
2022 - 05 - 06
1
2022 - 04 - 12
1
2021 - 10 - 19
1
2021 - 09 - 09
1
2021 - 08 - 13
1
2021 - 05 - 26
1
2021 - 04 - 12
1
2021 - 03 - 24
1
2021 - 02 - 17
1
2021 - 01 - 26
1
2020 - 12 - 28
1
Sector
Consumer durables
1
Finance
1
Health technology
14
Tags
Announces collaboration
1
Application
3
Approval
2
Bleeding
1
Collaboration
1
Commercialization
1
Contraceptive
1
Drug
4
Fda
4
Fda acceptance
1
Fda approval
1
Health
1
Lancet
1
Management
3
Menstrual bleeding
1
Merge
1
Myfembree
4
N/a
12
New drug
1
People
1
Pharm-country
1
Phase 3
5
Positive
2
Publication
1
Sciences
3
Therapy
5
Treatment
2
Uterine fibroids
1
Women
3
Entities
Abbott laboratories
32
Abbvie inc.
37
Adc therapeutics sa
5
Aerie pharmaceuticals, inc.
5
Agios pharmaceuticals, inc.
10
Alkermes plc
4
Alnylam pharmaceuticals, inc.
14
Amgen inc.
34
Arvinas, inc.
24
Astellas pharma inc
26
Astrazeneca plc
45
Aveo pharmaceuticals, inc.
10
Bausch health companies inc.
5
Baxter international inc.
6
Beam therapeutics inc.
6
Becton, dickinson and company
6
Beigene, ltd.
10
Biocryst pharmaceuticals, inc.
14
Biohaven pharmaceutical holding company ltd.
15
Biomarin pharmaceutical inc.
4
Biontech se
95
Blueprint medicines corporation
10
Bristol-myers squibb company
61
Clovis oncology, inc.
11
Eli lilly and company
80
Endo international plc
7
Epizyme, inc.
11
Exelixis, inc.
13
Genmab a/s
4
Gilead sciences, inc.
27
Glaxosmithkline plc
64
Global blood therapeutics, inc.
6
Ideaya biosciences, inc.
4
Illumina, inc.
12
Incyte corporation
14
Ionis pharmaceuticals, inc.
5
Johnson & johnson
76
Karyopharm therapeutics inc.
10
Moderna, inc.
7
Morgan stanley
4
Myovant sciences ltd.
14
Neurocrine biosciences, inc.
4
Novartis ag
88
Novo nordisk a/s
11
Omeros corporation
13
Opko health, inc.
6
Orange
29
Otonomy, inc.
13
Pfizer, inc.
693
Regeneron pharmaceuticals, inc.
22
Rigel pharmaceuticals, inc.
11
Sanofi
153
Seagen inc.
7
Takeda pharmaceutical company limited
23
Teva pharmaceutical industries ltd
29
Verastem, inc.
10
Viatris inc.
8
Voyager therapeutics, inc.
6
Xeris pharmaceuticals, inc.
10
Y-mabs therapeutics, inc.
10
Symbols
ABT
1
ABUS
1
ALPMF
1
ALPMY
1
CS
1
DMTK
1
EXAS
1
EXEL
1
F
1
FDMT
1
FNCTF
3
JNJ
1
MS
1
MYOV
124
NMTR
1
PFE
14
PHAT
2
Exchanges
Nasdaq
1
Nyse
14
Crawled Date
2022 - 08 - 06
1
2022 - 06 - 17
1
2022 - 06 - 02
1
2022 - 05 - 06
1
2022 - 04 - 12
1
2021 - 10 - 19
1
2021 - 09 - 09
1
2021 - 08 - 13
1
2021 - 05 - 26
1
2021 - 04 - 12
1
2021 - 03 - 24
1
2021 - 02 - 17
1
2021 - 01 - 26
1
2020 - 12 - 28
1
Crawled Time
04:20
1
05:00
1
11:00
7
12:00
3
21:00
1
22:04
1
Source
www.biospace.com
2
www.globenewswire.com
12
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Myovant sciences ltd.
symbols :
PFE
save search
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Published:
2022-08-06
(Crawled : 04:20)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
Email alert
Add to watchlist
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
Email alert
Add to watchlist
myfembree
treatment
fda
sciences
management
approval
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Published:
2022-06-17
(Crawled : 11:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-45.09%
|
O:
-0.74%
H:
0.0%
C:
0.0%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
156.22%
|
O:
3.13%
H:
8.66%
C:
6.63%
sciences
women
lancet
therapy
publication
phase 3
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
Published:
2022-06-02
(Crawled : 11:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-50.6%
|
O:
-1.62%
H:
0.0%
C:
0.0%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
155.37%
|
O:
-2.98%
H:
0.0%
C:
0.0%
myfembree
fda
sciences
drug
application
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Published:
2022-05-06
(Crawled : 11:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-46.76%
|
O:
-2.36%
H:
0.0%
C:
0.0%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
179.59%
|
O:
-1.71%
H:
0.0%
C:
0.0%
myfembree
management
drug
application
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
Published:
2022-04-12
(Crawled : 05:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-51.31%
|
O:
-1.17%
H:
1.18%
C:
-0.36%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
94.52%
|
O:
-22.06%
H:
9.34%
C:
-3.89%
myfembree
management
drug
application
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
Published:
2021-10-19
(Crawled : 11:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-36.45%
|
O:
0.68%
H:
1.44%
C:
1.18%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
33.1%
|
O:
0.3%
H:
3.0%
C:
-0.15%
uterine fibroids
therapy
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Published:
2021-09-09
(Crawled : 11:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-43.54%
|
O:
-0.09%
H:
0.53%
C:
-0.95%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
4.53%
|
O:
-0.54%
H:
1.56%
C:
-2.22%
new drug
fda
fda acceptance
drug
Alpha Healthcare and Humacyte Announce Nominees for Election to Post-Merger Public Company Board of Directors
Published:
2021-08-13
(Crawled : 12:00)
- biospace.com/
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-44.41%
|
O:
0.55%
H:
0.0%
C:
0.0%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
22.25%
|
O:
0.27%
H:
0.0%
C:
0.0%
MS
|
News
0 d
|
$92.09
1.58%
0.01%
7.3M
|
Finance
|
-12.02%
|
O:
-0.11%
H:
0.0%
C:
0.0%
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-14.89%
|
O:
-0.09%
H:
0.0%
C:
0.0%
F
|
News
|
$12.88
6.1%
-0.04%
86M
|
Consumer Durables
|
-7.34%
|
O:
0.04%
H:
0.0%
C:
0.0%
CS
|
$0.8858
1.49%
64M
|
Finance
|
-91.51%
|
O:
-0.34%
H:
0.0%
C:
0.0%
EXAS
|
$62.41
2.38%
2.32%
1.6M
|
Health Technology
|
-35.21%
|
O:
1.64%
H:
0.0%
C:
0.0%
DMTK
4
|
$0.636
-1.24%
-1.26%
210K
|
Health Technology
|
-98.39%
|
O:
0.86%
H:
0.0%
C:
0.0%
NMTR
|
$0.0722
-42.97%
-67.9%
10M
|
Health Technology
|
-93.19%
|
O:
-0.94%
H:
0.0%
C:
0.0%
merge
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
Published:
2021-05-26
(Crawled : 21:00)
- biospace.com/
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-33.23%
|
O:
-0.1%
H:
0.03%
C:
-0.94%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
18.39%
|
O:
0.26%
H:
8.97%
C:
3.63%
treatment
fda
bleeding
fda approval
approval
menstrual bleeding
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
Published:
2021-04-12
(Crawled : 11:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-28.25%
|
O:
-0.33%
H:
1.52%
C:
1.34%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
48.65%
|
O:
-0.39%
H:
0.5%
C:
-4.98%
phase 3
contraceptive
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Published:
2021-03-24
(Crawled : 11:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-25.74%
|
O:
0.34%
H:
1.27%
C:
0.37%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
15.3%
|
O:
0.3%
H:
1.17%
C:
-7.12%
positive
therapy
women
phase 3
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Published:
2021-02-17
(Crawled : 22:04)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-24.73%
|
O:
-0.32%
H:
0.28%
C:
-0.63%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
20.66%
|
O:
-0.89%
H:
3.7%
C:
3.11%
therapy
women
phase 3
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published:
2021-01-26
(Crawled : 12:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-29.56%
|
O:
-0.03%
H:
0.89%
C:
0.11%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
30.28%
|
O:
4.44%
H:
9.52%
C:
4.67%
positive
therapy
phase 3
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Published:
2020-12-28
(Crawled : 12:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-29.54%
|
O:
0.24%
H:
0.59%
C:
-1.45%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
18.59%
|
O:
32.66%
H:
2.39%
C:
-9.18%
collaboration
commercialization
announces collaboration
health
Gainers vs Losers
75%
25%
Top 10 Gainers
MTTR
|
News
M
|
$4.78
174.71%
63.6%
72M
|
AGBA
|
$2.565
105.2%
51.27%
200M
|
Finance
MLEC
|
$2.44
74.29%
42.62%
78M
|
n/a
EDBL
|
News
|
$6.28
67.02%
40.13%
16M
|
ATGL
|
$2.91
48.81%
32.8%
180K
|
ZAPP
|
$0.2175
47.16%
32.05%
16M
|
n/a
ONFO
|
$0.6075
38.38%
27.74%
7.3M
|
n/a
VIVK
|
$1.48
38.32%
27.7%
530K
|
Professional, Scientific, and T...
MNTS
|
$0.5
35.69%
26.3%
4.8M
|
SDIG
A
|
$3.635
35.13%
26.0%
1M
|
Your saved searches
Save your searches and get alerts when important news are released.